TINUBU-SQUARE
Tinubu® Square Group, the global technology leader in the surety and credit insurance industry, announced today it has acquired the assets of SuretyWave LLC, including its technology and knowledge base, notably the cloud-based surety bond processing system known as SurePath Digital.
The acquisition continues Tinubu Square’s execution of its global strategic vision of building highly complementary and integrated enterprise software solutions and services for credit and surety insurers. This enables clients, brokers, agents, obligees, and carriers to manage their rapidly evolving, high-growth businesses efficiently.
With the acquisition, Tinubu Square’s end-to-end SaaS platform simplifies processing for an entire value chain that has long struggled with disparate, complex surety bond information. Agents, brokers and carrier partners can now efficiently manage their bond requirements, premiums, commission and other calculations.
Tinubu Square is the global leader in designing, producing and servicing the largest providers of financial guarantee products. The Paris-based firm provides technology solutions to 30 of the top 60 credit and surety underwriters in the United States and globally.
Jérôme Pezé, co-founder and CEO, says, “We are now even closer to a global promise of full automation and digitalization of surety and credit insurance products.”
SurePath Digital “is an outstanding insurtech solution because of its proven ability to streamline connections for independent agencies and brokers, which are key business partners to carriers that stand behind bonds,” Pezé adds. “These bond producers add significant value for customers, but desperately need the appropriate technology solution for their business to reduce manual processing, be more efficient for their customers, and grow profitably.”
Earlier this year, Tinubu Square acquired another U.S.-based insurtech, eSURETY®, which provides cloud-based solutions for automated underwriting, account risk analysis, bond lifecycle management and surety analytics at an enterprise level.
“The Tinubu eSURETY solution, its team’s expertise, and its brand recognition brought highly complementary capabilities to our combined existing and future customers,” says Pezé. “What that platform provides for surety carriers, SurePath Digital does for agents and brokers. SurePath significantly reduces the cost of executing and managing surety bonds through automation of administration, processing and reporting functions.
“These capabilities have strengthened our position in the global surety marketplace, providing an end-to-end cloud-based platform,” Pezé adds.
Daniel T. Buckles, deputy CEO and president, surety, of Tinubu Square Americas, notes that the surety bond business “is highly complex but too often still paper-based for multiline agents and brokers and their carrier partners. SurePath Digital is the key to continue to make it less cumbersome so our partners can focus on completing deals. We are building technology bridges in the surety industry where there have been none.”
“We are excited for SurePath Digital to be aligned with an industry leader in Tinubu Square,” says W. Patrick McGinty CPCU, president of SuretyWave. “Existing clients of Tinubu eSURETY and SuretyWave continue to be in safe hands, as the companies concentrate on sustainability and continuity for their software users. Tinubu Square has the same determined focus, innovative technology, and customer-centricity that provide a best-in-class customer experience and product.”
Olivier Placca, Tinubu Square co-founder and group deputy CEO, states, “By investing 20% of revenue in research and development on a yearly basis, Tinubu Square will support further innovation for the benefit of SurePath Digital’s clients. It reinforces our commitment to making this a long-term partnership.”
Placca adds: “Our solution can grow and make an even more significant positive impact in the surety business. Tinubu Square’s enterprise solutions lead the way in supporting an open ecosystem for all players in the surety and credit insurance industry. We are reducing the duplication of tasks, including the many manual tasks still in use. This reduces administrative costs, improves processes and operations, and eases the two-way communication between brokers and agents with underwriters.”
About SuretyWave
In 2017, Steckler Group acquired Insure Vision Technologies (IVT) and renamed the company as SuretyWave. IVT, founded in 1999, was formed to develop a cloud-based surety bond processing system that significantly reduces the cost of executing and managing surety bonds. IVT founders Pam Stocks and Bev Hall helped lead surety industry efforts by being active with ACORD’s standard setting committee for electronic interface between carriers and brokers/agents and with the National Association of Surety Bond Producers (NASBP) Surety Automation Committee and Commercial Surety Committee.
About Tinubu Square
Tinubu® Square is the industry-leading insurtech SaaS (software as a service) platform vendor, enabling credit insurance and surety digital transformation. With 170+ employees globally and 20 years of innovation, Tinubu Square empowers its customers to offer best-in-class client experience; reduce exposure to risk; and lower financial, operational and technology costs. The firm has a footprint with customers in over 20 countries, including 30 of the top 60 worldwide credit and surety underwriters and invests 20% of its annual revenue in research and development. Visit www.tinubu.com/
for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005715/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
